These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 7865327)

  • 1. Panel discussion on vaccine development to meet U.S. and international needs. Perspectives on national and global HIV vaccine development: potential ways to reduce impediments for biopharmaceutical product development.
    Obijeski J
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S307-8. PubMed ID: 7865327
    [No Abstract]   [Full Text] [Related]  

  • 2. Panel discussion on vaccine development to meet U.S. and international needs. When manufacturers are unwilling to accept the risks or invest the capital: vaccine production by the Salk Institute to specifications of the U.S. Army.
    French GR
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S309. PubMed ID: 7865328
    [No Abstract]   [Full Text] [Related]  

  • 3. Panel discussion on vaccine development to meet U.S. and international needs. Strategies for reducing the disincentives to HIV vaccine development: description of a successful public-private sector international collaboration.
    Bronnenkant L
    AIDS Res Hum Retroviruses; 1994; 10 Suppl 2():S311-3. PubMed ID: 7865329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Private investment in AIDS vaccine development: obstacles and solutions.
    Batson A; Ainsworth M
    Bull World Health Organ; 2001; 79(8):721-7. PubMed ID: 11545328
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AIDS vaccine 'needs focused effort' as drug firms back off research.
    Butler D
    Nature; 1995 Nov; 378(6555):323-4. PubMed ID: 7477355
    [No Abstract]   [Full Text] [Related]  

  • 6. Advocacy group sees little progress toward an HIV vaccine.
    AIDS Policy Law; 1998 May; 13(10):1, 8-9. PubMed ID: 11365444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NIAID funds new groups to develop HIV vaccines.
    Watanabe ME
    Nat Med; 2000 Aug; 6(8):844. PubMed ID: 10932202
    [No Abstract]   [Full Text] [Related]  

  • 8. Medicine. The need for a global HIV vaccine enterprise.
    Klausner RD; Fauci AS; Corey L; Nabel GJ; Gayle H; Berkley S; Haynes BF; Baltimore D; Collins C; Douglas RG; Esparza J; Francis DP; Ganguly NK; Gerberding JL; Johnston MI; Kazatchkine MD; McMichael AJ; Makgoba MW; Pantaleo G; Piot P; Shao Y; Tramont E; Varmus H; Wasserheit JN
    Science; 2003 Jun; 300(5628):2036-9. PubMed ID: 12829768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progenics to develop HIV vaccine.
    Expert Rev Vaccines; 2004 Jun; 3(3):229-30. PubMed ID: 15176938
    [No Abstract]   [Full Text] [Related]  

  • 10. Funding support lacking in search for HIV vaccine.
    AIDS Alert; 1999 Jan; 14(1):5-7. PubMed ID: 11366091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NIAID and Merck to collaborate on HIV vaccine development.
    AIDS Read; 2002 Feb; 12(2):60. PubMed ID: 11905140
    [No Abstract]   [Full Text] [Related]  

  • 12. Market incentives, human lives, and AIDS vaccines.
    Craddock S
    Soc Sci Med; 2007 Mar; 64(5):1042-56. PubMed ID: 17113203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine development moves to front burner.
    AIDS Alert; 1997 Mar; 12(3):32-3. PubMed ID: 11364191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV vaccine strategy seeks to woo industry.
    Wadman M
    Nature; 1996 Feb; 379(6567):665. PubMed ID: 8602205
    [No Abstract]   [Full Text] [Related]  

  • 15. NIAID funds center for HIV/AIDS vaccine immunology.
    AIDS Policy Law; 2005 Jul; 20(14):2. PubMed ID: 16108120
    [No Abstract]   [Full Text] [Related]  

  • 16. Vaccine legislation.
    AIDS Policy Law; 1999 Jul; 14(13):16. PubMed ID: 11366597
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinton sets goal of having an AIDS vaccine in 10 years.
    AIDS Policy Law; 1997 Jun; 12(11):3. PubMed ID: 11364387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global HIV vaccine enterprise appoints new director.
    McEnery R
    IAVI Rep; 2012; 16(2):20-1. PubMed ID: 22650057
    [No Abstract]   [Full Text] [Related]  

  • 19. Industrial strength research. Collaborative efforts in AIDS vaccine research are adopting some characteristics common in the biopharmaceutical industry.
    Zandonella C
    IAVI Rep; 2006; 10(1):1, 6-8. PubMed ID: 16625718
    [No Abstract]   [Full Text] [Related]  

  • 20. HIV vaccine developers battle on, despite high-profile failures.
    Ledford H
    Nat Biotechnol; 2008 Jun; 26(6):591-2. PubMed ID: 18536659
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.